Emtricitabine + FamciclovirUnknown
7 DRUG INTERACTIONS The potential for drug interactions with EMTRIVA has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF).
Source: FDA drug label - emtricitabine
Emtricitabine Interactions
Brand names: Emtricitabine
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor · Nucleoside Reverse Transcriptase Inhibitors
FDA Black Box Warning
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued emtricitabine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue emtricitabine. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of Hepatitis B (HBV) have been reported in patients coinfected with HIV-1 and HBV who have discontinued emtricitabine. Hepatic function should be monitored closely in patients coinfected with HIV-1 and HBV who discontinue emtricitabine. If appropriate, initiation of anti-hepatitis B therapy may be warranted. ( 5.1 )
3 interactions on record
Emtricitabine + IndinavirUnknown
7 DRUG INTERACTIONS The potential for drug interactions with EMTRIVA has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF).
Source: FDA drug label - emtricitabine
Emtricitabine + TenofovirUnknown
7 DRUG INTERACTIONS The potential for drug interactions with EMTRIVA has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF).
Source: FDA drug label - emtricitabine